Elutia (ELUT) to Announce Quarterly Earnings on Thursday

Elutia (NASDAQ:ELUT) is expected to post its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect Elutia to post earnings of ($0.15) per share and revenue of $2.90 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 5:00 PM ET.

Elutia (NASDAQ:ELUT) last released its earnings results on Thursday, May 14th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The company had revenue of $3.11 million for the quarter, compared to analyst estimates of $3.00 million.

Elutia Trading Down 4.2%

NASDAQ ELUT opened at $0.81 on Tuesday. The firm’s fifty day moving average price is $0.95 and its two-hundred day moving average price is $1.04. Elutia has a 1 year low of $0.50 and a 1 year high of $2.50. The firm has a market capitalization of $34.82 million, a P/E ratio of 0.95 and a beta of 0.87.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Elutia from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 23rd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $6.00.

Institutional Investors Weigh In On Elutia

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Deerfield Management Company L.P. acquired a new position in shares of Elutia during the 3rd quarter worth approximately $1,221,000. XTX Topco Ltd acquired a new stake in Elutia during the fourth quarter worth approximately $71,000. Citadel Advisors LLC acquired a new stake in Elutia during the third quarter worth approximately $50,000. Renaissance Technologies LLC increased its stake in Elutia by 64.7% during the 4th quarter. Renaissance Technologies LLC now owns 102,116 shares of the company’s stock worth $71,000 after acquiring an additional 40,123 shares during the period. Finally, Virtu Financial LLC acquired a new position in Elutia in the 3rd quarter valued at $26,000. Institutional investors and hedge funds own 74.03% of the company’s stock.

Elutia Company Profile

Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small?molecule donors.

The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.